172 related articles for article (PubMed ID: 17608406)
21. Modeling, analysis, and validation of a novel HIV integrase structure provide insights into the binding modes of potent integrase inhibitors.
Chen X; Tsiang M; Yu F; Hung M; Jones GS; Zeynalzadegan A; Qi X; Jin H; Kim CU; Swaminathan S; Chen JM
J Mol Biol; 2008 Jul; 380(3):504-19. PubMed ID: 18565342
[TBL] [Abstract][Full Text] [Related]
22. Toward novel HIV-1 integrase binding inhibitors: molecular modeling, synthesis, and biological studies.
Mugnaini C; Rajamaki S; Tintori C; Corelli F; Massa S; Witvrouw M; Debyser Z; Veljkovic V; Botta M
Bioorg Med Chem Lett; 2007 Oct; 17(19):5370-3. PubMed ID: 17716893
[TBL] [Abstract][Full Text] [Related]
23. Study on the molecular mechanism of inhibiting HIV-1 integrase by EBR28 peptide via molecular modeling approach.
Hu JP; Gong XQ; Su JG; Chen WZ; Wang CX
Biophys Chem; 2008 Feb; 132(2-3):69-80. PubMed ID: 18037557
[TBL] [Abstract][Full Text] [Related]
24. Symmetrical 1-pyrrolidineacetamide showing anti-HIV activity through a new binding site on HIV-1 integrase.
Du L; Zhao YX; Yang LM; Zheng YT; Tang Y; Shen X; Jiang HL
Acta Pharmacol Sin; 2008 Oct; 29(10):1261-7. PubMed ID: 18817633
[TBL] [Abstract][Full Text] [Related]
25. Characterization and structural analysis of HIV-1 integrase conservation.
Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
[TBL] [Abstract][Full Text] [Related]
26. HIV-1 integrase inhibitors: 2007-2008 update.
Ramkumar K; Serrao E; Odde S; Neamati N
Med Res Rev; 2010 Nov; 30(6):890-954. PubMed ID: 20135632
[TBL] [Abstract][Full Text] [Related]
27. A docking study of L-chicoric acid with HIV-1 integrase.
Healy EF; Sanders J; King PJ; Robinson WE
J Mol Graph Model; 2009 Jan; 27(5):584-9. PubMed ID: 19004651
[TBL] [Abstract][Full Text] [Related]
28. Development of a fluorescence-based HIV-1 integrase DNA binding assay for identification of novel HIV-1 integrase inhibitors.
Han YS; Xiao WL; Quashie PK; Mesplède T; Xu H; Deprez E; Delelis O; Pu JX; Sun HD; Wainberg MA
Antiviral Res; 2013 Jun; 98(3):441-8. PubMed ID: 23583286
[TBL] [Abstract][Full Text] [Related]
29. Pharmacophore-based discovery of small-molecule inhibitors of protein-protein interactions between HIV-1 integrase and cellular cofactor LEDGF/p75.
De Luca L; Barreca ML; Ferro S; Christ F; Iraci N; Gitto R; Monforte AM; Debyser Z; Chimirri A
ChemMedChem; 2009 Aug; 4(8):1311-6. PubMed ID: 19565598
[TBL] [Abstract][Full Text] [Related]
30. HIV type 1 integrase inhibitors: from basic research to clinical implications.
Jegede O; Babu J; Di Santo R; McColl DJ; Weber J; Quiñones-Mateu M
AIDS Rev; 2008; 10(3):172-89. PubMed ID: 18820719
[TBL] [Abstract][Full Text] [Related]
31. Dissecting Tn5 transposition using HIV-1 integrase diketoacid inhibitors.
Czyz A; Stillmock KA; Hazuda DJ; Reznikoff WS
Biochemistry; 2007 Sep; 46(38):10776-89. PubMed ID: 17725323
[TBL] [Abstract][Full Text] [Related]
32. Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.
Li HY; Zawahir Z; Song LD; Long YQ; Neamati N
J Med Chem; 2006 Jul; 49(15):4477-86. PubMed ID: 16854053
[TBL] [Abstract][Full Text] [Related]
33. Diketo acid pharmacophore. 2. Discovery of structurally diverse inhibitors of HIV-1 integrase.
Dayam R; Sanchez T; Neamati N
J Med Chem; 2005 Dec; 48(25):8009-15. PubMed ID: 16335925
[TBL] [Abstract][Full Text] [Related]
34. HIV integrase inhibitors as therapeutic agents in AIDS.
Nair V; Chi G
Rev Med Virol; 2007; 17(4):277-95. PubMed ID: 17503547
[TBL] [Abstract][Full Text] [Related]
35. Docking dinucleotides to HIV-1 integrase carboxyl-terminal domain to find possible DNA binding sites.
Zhu HM; Chen WZ; Wang CX
Bioorg Med Chem Lett; 2005 Jan; 15(2):475-7. PubMed ID: 15603976
[TBL] [Abstract][Full Text] [Related]
36. De novo design and synthesis of HIV-1 integrase inhibitors.
Makhija MT; Kasliwal RT; Kulkarni VM; Neamati N
Bioorg Med Chem; 2004 May; 12(9):2317-33. PubMed ID: 15080929
[TBL] [Abstract][Full Text] [Related]
37. A refined pharmacophore model for HIV-1 integrase inhibitors: Optimization of potency in the 1H-benzylindole series.
De Luca L; Barreca ML; Ferro S; Iraci N; Michiels M; Christ F; Debyser Z; Witvrouw M; Chimirri A
Bioorg Med Chem Lett; 2008 May; 18(9):2891-5. PubMed ID: 18417342
[TBL] [Abstract][Full Text] [Related]
38. Discovery of structurally diverse HIV-1 integrase inhibitors based on a chalcone pharmacophore.
Deng J; Sanchez T; Al-Mawsawi LQ; Dayam R; Yunes RA; Garofalo A; Bolger MB; Neamati N
Bioorg Med Chem; 2007 Jul; 15(14):4985-5002. PubMed ID: 17502148
[TBL] [Abstract][Full Text] [Related]
39. HIV-1 integrase inhibitors: 2005-2006 update.
Dayam R; Gundla R; Al-Mawsawi LQ; Neamati N
Med Res Rev; 2008 Jan; 28(1):118-54. PubMed ID: 17979144
[TBL] [Abstract][Full Text] [Related]
40. Tn5 transposase as a useful platform to simulate HIV-1 integrase inhibitor binding mode.
Barreca ML; Ortuso F; Iraci N; De Luca L; Alcaro S; Chimirri A
Biochem Biophys Res Commun; 2007 Nov; 363(3):554-60. PubMed ID: 17889829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
